Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5853 | 509077-98-9 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Catumaxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is specifically directed against the epithelial cell adhesion molecule (EpCAM) and the CD3 antigen. The EpCAM antigen is expressed on most cancers especially carcinomas. CD3 is expressed on mature T-cells as a component of the T-cell receptor. A third functional binding site in the Fc-region of catumaxomab enables interaction with accessory immune cells via Fc-gamma receptors. Due to catumaxomab’s binding properties, tumour cells, T-cells and accessory immune cells come in close proximity. Thereby, a concerted immunoreaction against tumour cells is induced which includes different mechanisms of action such as T-cell activation, T-cell mediated killing via the granzyme / perforin system, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and phagocytosis. This results in destruction of tumour cells in the peritoneal cavity, thereby eliminating a major cause of malignant ascites.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 10, 2025 | EMA | Atnahs Pharma Netherlands B.V. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FX03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates |
| MeSH PA | D005765 | Gastrointestinal Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Malignant ascites in adults with EpCAM-positive epithelial carcinomas | indication | 236005001 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Epithelial cell adhesion molecule | Membrane other | ANTIBODY BINDING | UNKNOWN | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL2108581 | ChEMBL_ID |
| C522419 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB06607 | DRUGBANK_ID |
| C1831854 | UMLSCUI |
| CHEBI:753535 | CHEBI |
| 8406 | INN_ID |
| 7385 | IUPHAR_LIGAND_ID |
| M2HPV837HO | UNII |
| 712557008 | SNOMEDCT_US |
| D09207 | KEGG_DRUG |
| 013957 | NDDF |
None